Clinical data | |
---|---|
Other names | BAY-3427080; GSK-1144814; NT-814 |
Routes of administration | Oral administration |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C33H35F7N4O3 |
Molar mass | 668.657 g·mol−1 |
3D model ( JSmol) | |
| |
|
Elinzanetant (developmental code names BAY-3427080 GSK-1144814, NT-814) is an orally active small-molecule neurokinin/tachykinin NK1 receptor and NK3 receptor antagonist which is under development by Bayer, GlaxoSmithKline, and NeRRe Therapeutics for the treatment of hot flashes and "sex hormone disorders". [1] [2] It has been found to relieve hot flashes in postmenopausal women and to dose-dependently suppress luteinizing hormone, estradiol, and progesterone levels in premenopausal women. [2] [3] As of August 2021, elinzanetant is in phase 2 clinical trials for hot flashes and "sex hormone disorders". [1] It was also under development for the treatment of schizophrenia and opioid-related disorders, but development was discontinued for these uses. [1]
Clinical data | |
---|---|
Other names | BAY-3427080; GSK-1144814; NT-814 |
Routes of administration | Oral administration |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C33H35F7N4O3 |
Molar mass | 668.657 g·mol−1 |
3D model ( JSmol) | |
| |
|
Elinzanetant (developmental code names BAY-3427080 GSK-1144814, NT-814) is an orally active small-molecule neurokinin/tachykinin NK1 receptor and NK3 receptor antagonist which is under development by Bayer, GlaxoSmithKline, and NeRRe Therapeutics for the treatment of hot flashes and "sex hormone disorders". [1] [2] It has been found to relieve hot flashes in postmenopausal women and to dose-dependently suppress luteinizing hormone, estradiol, and progesterone levels in premenopausal women. [2] [3] As of August 2021, elinzanetant is in phase 2 clinical trials for hot flashes and "sex hormone disorders". [1] It was also under development for the treatment of schizophrenia and opioid-related disorders, but development was discontinued for these uses. [1]